TOKYO and CAMBRIDGE, England, Feb. 1, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) announces it will apply its world-leading structure-based drug design (SBDD) expertise and ...
The review has been published online in Trends in Pharmacological Sciences, a Cell Press publication, and will appear in a special issue of the journal in May, which focuses on structure-based drug ...
Researchers used both ligand-based drug design (LBDD) and structure-based drug design (SBDD) strategies within the Chemistry42 generative chemistry engine for molecular generation. Building on the ...
HTL’149 has been designed as a once-daily oral treatment to address positive and negative symptoms and cognitive impairment in schizophrenia patients without the adverse effects typically associated ...
Structure-Based Drug Design (SBDD) has evolved a graphic (Small)great deal over the past 30 years since the concept of the “Lock and Key” hypothesis was first reduced to practice in the HIV-1 protease ...
Structural biology and computational chemistry can combine to accelerate the delivery of clinical candidates with excellent overall profiles. For instance, today it is possible to use state-of-the art ...
Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences Ion channels represent a large but ...
CAMBRIDGE, England & TOKYO--(BUSINESS WIRE)--Metrion Biosciences Limited (“Metrion”), the specialist ion channel CRO and drug discovery company and Sosei Group Corporation (“the Company”; TSE: 4565), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results